Safety considerations when prescribing immunosuppression medication to pregnant women

Expert Opinion on Drug Safety

Volumn 13, Issue 12, 2014, Pages 1591-1599

  Gerosa, Maria ^a   Meroni, Pier Luigi ^a   Cimaz, Rolando ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Azathioprine; Biological agents; Cyclosporine; Immunosuppressive drugs; Leflunomide; Methotrexate; Mycophenolate mofetil; Pregnancy; Steroids; TNF inhibitors

Indexed keywords

ADALIMUMAB; ANTIMALARIAL AGENT; AZATHIOPRINE; BELIMUMAB; CERTOLIZUMAB PEGOL; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

CEREBRAL PALSY; CONGENITAL DISORDER; CRANIOFACIAL SYNOSTOSIS; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG SAFETY; EMBRYOPATHY; EMBRYOTOXICITY; EYE TOXICITY; FEMALE; FETUS MALFORMATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAUTERINE GROWTH RETARDATION; LIMB DEFECT; LOW BIRTH WEIGHT; MATERNAL HYPERTENSION; NONHUMAN; OSTEOPOROSIS; OTOTOXICITY; PATIENT SAFETY; PREECLAMPSIA; PREGNANT WOMAN; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PREMATURITY; PRESCRIPTION; PSYCHOMOTOR DEVELOPMENT; PULMONARY VALVE ATRESIA; REVIEW; SPONTANEOUS ABORTION; UNILATERAL BLINDNESS; ANIMAL; PREGNANCY; RHEUMATIC DISEASES;

ANIMALS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PREGNANCY; RHEUMATIC DISEASES;

EID: 84912038557     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.951326     Document Type: Review

References (56)

1. Stojan G, Baer AN. Flares of systemic lupus erythematosus during pregnancy and the puerperium: prevention, diagnosis and management. Expert Rev Clin Immunol 2012;8:439-53
2. De Man YA, Hazes JMW, van der Heide H, et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight. Arthritis Rheum 2009;60:3196-206
3. Taraborelli M, Ramoni V, Brucato A, et al. Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: An Italian multicenter study. Arthritis Rheum 2012;64:1970-7
4. Nielsen OH, Loftus EV Jr, Jess T. Safety of TNF-Alpha inhibitors during IBD pregnancy: A systematic review. BMC Med 2013;11:174
5. Blanford AT, Murphy BE. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol 1977;127:264-7
6. Pinsky L, Digeorge AM. Cleft palate in the mouse: A teratogenic index of glucocorticoid potency. Science 1965;147:402-3
7. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-Analysis of epidemiological studies. Teratology 2000;6:385-92
8. Carmichael SL, Shaw GM. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007;197:585-92
9. Gur C, Diav-Citrin O, Shechtman S, et al. Pregnancy outcome after first trimester exposure to glucocorticosteroids: A prospective controlled trial. Reprod Toxicol 2004;18:93-101
10. Han AR, Ahn H, Vu P, et al. Obstetrical outcome of anti-inflammatory and anticoagulation therapy in women with recurrent pregnancy loss or unexplained infertility. Am J Reprod Immunol 2012;68:418-27
11. Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 2011;183:796-804
12. Ostensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006;8:209-15
13. Owen D, Matthews SG. Repeated maternal glucocorticoid treatment affects activity and hippocampal NMDA receptor expression in juvenile guinea pigs. J Physiol 2007;578:249-57
14. French NP, Hagan R, Evans SF, et al. Repeated antenatal corticosteroids: effects on cerebral palsy and childhood behavior. Am J Obstet Gynecol 2004;190:588-95
15. Khalife N, Glover V, Taanila A, et al. Prenatal glucocorticoid treatment and later mental health in children and adolescents. PLoS One 2013;8:e813994
16. de Steenwinkel FD, Hokken-Koelega AC, Hazes JM, et al. Brief report: does medication use or disease activity during pregnancy in patients with rheumatoid arthritis affect bone density in their prepubertal offspring? Arthritis Rheumatol 2014;66:533-7
17. Clowse ME, Magder L, Witter F, et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006;54:3640-7
18. Peart E, Clowse MEB. Systemic lupus erythematosus and pregnancy outcomes: An update and review of the literature. Curr Opin Rheumatol 2014;26:118-23
19. Izmirly PM, Saxena A, Kim MY, et al. Maternal and fetal factors associated with mortality and morbidity in a multiracial/etnic registry of anti-SSA/Roassociated cardiac neonatal lupus. Circulation 2011;124:1927-35
20. Ostensen M, Forger F. How safe are anti-rheumatic drugs during pregnancy? Curr Opin Pharmacol 2013;13:470-5
21. Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. Curr Opin Rheumatol 2014;26:334-40
22. Radomski JS, Ahlswede BA, Jarrell BE, et al. Outcomes of 500 pregnancies in 335 female kidney, liver, and heart transplant recipients. Transplant Proc 1995;27:1089-90
23. Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-Analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:15-22
24. Ban L, Tata LJ, Fiaschi L, Card T. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. Gastroenterology 2014;146:76-84
25. Paziana K, Del Monaco M, Cardonick E, et al. Cyclosporin use during pregnancy. Drug Saf 2013;36:279-29
26. Cimaz R, Meregalli E, Biggioggero M, et al. Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy. Toxicol Lett 2004;149:155-62
27. Biggioggero M, Borghi MO, Gerosa M, et al. Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants. Lupus 2007;16:651-6
28. Hyoun SC, Obic?an SG, Scialli AR. Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol 2012;94:187-207
29. Feldkamp M, Carey JC. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology 1993;47:533-9
30. Martn MC, Barbero P, Groisman B, et al. Methotrexate embryopathy after exposure to low weekly doses in early pregnancy. Reprod Toxicol 2014;43:26-9
31. Nurmohamed L, Moretti ME, Schechter T, et al. Outcome following high-dose methotrexate in pregnancies misdiagnosed as ectopic. Am J Obstet Gynecol 2011;205:533
32. Poggi SH, Ghidini A. Importance of timing of gestational exposure to methotrexate for its teratogenic effects when used in setting of misdiagnosis of ectopic pregnancy. Fertil Steril 2011;96:669-71
33. Cooper WO, Cheetham TC, Li DK, et al. Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immunemediated diseases and pregnancy. Arthritis Rheumatol 2014;66:444-50
34. Weber-Schoendorfer C, Chambers C, Wacker E, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: A prospective multicenter cohort study. Arthritis Rheumatol 2014;66:1101-10
35. Kim SC, Hernandez-Diaz S. Safety of immunosuppressive drugs in pregnant women with systemic inflammatory diseases. Arthritis Rheumatol 2014;66:246-9
36. Brent RL. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 2001;63:106-12
37. Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010;62:1494-503
38. Cassina M, Johnson DL, Robinson LK, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum 2012;64:2085-94
39. Harvard LE, Mithcel K, Piepel C. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus 2013;22:81-6
40. Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995;17:681-4
41. Kim M, Rostas S, Gabardi S. Mycophenolate fetal toxicity and risk evaluation and mitigation strategies. Am J Transplant 2013;13:1383-9
42. Merlob P, Stahl B, Klinger G. Tetrada of the possible mycophenolate mofetil embryopathy: A review. Reprod Toxicol 2009;28:105-8
43. Anderka MT, Lin AE, Abuelo DN, et al. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A 2009;149A:1241-8
44. Hoeltzenbein M, Elefant E, Vial T, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A 2012;158A:588-96
45. Mohamed-Ahmed O, Nelson-Piercy C, Bramham K, et al. Pregnancy outcomes in liver and cardiothoracic transplant recipients: A UK national cohort study. PLoS One 2014;9:e89151
46. Gabardi S. Understanding risk evaluation and mitigation strategies in organ transplantation. Pharmacotherapy 2011;31:714-22
47. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:286-92
48. Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: A review of the Food and Drug Administration database. J Rheumatol 2009;36:635-41
49. Ostensen M, Forger F. Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol 2011;23:293-8
50. Chambers CD, Johnson DL. Emerging data on the use of anti-tumor necrosis factor-Alpha medications in pregnancy. Birth Defects Res A Clin Mol Teratol 2012;94:607-11
51. Ostensen M. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann N Y Acad Sci 2014;1317:32-8
52. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood 2011;117:1499-506
53. Ojeda-Uribe M, Afif N, Dahan E, et al. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol 2013;32:695-700
54. Gualtierotti R, Ingegnoli F, Meroni PL. Pre-conceptional exposure to rituximab: comment on the article by Ojeda-Uribe et al. Clin Rheumatol 2013;32:727-8
55. Rubbert-Roth A, Goupille PM, Moosavi S, et al. First experiences with pregnancies in RA patients receiving tocilizumab therapy. Arthritis Rheum 2010;62:S161
56. Landy H, Powell M, Hill D, et al. Belimumab pregnancy registry: prospective cohort study of pregnancy outcomes. Obstet Gynecol 2014;123(Suppl 1):62S